Ga-NOTA-T4
Phase 3Small molecule
Ga-NOTA-T4 is one of 92 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
3
Indications
3
Total Trials
3
Active Trials
91
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Nano-Crystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
RC148
RRemeGen Co., Ltd.
Phase 3
Anktiva
SSWOG Cancer Research Network
Phase 3
Carboplatin/paclitaxel
AstraZenecaPhase 3
Ga-NOTA-T4
RRenJi Hospital
Phase 3
Remeron
OOrganon and Co
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ga-NOTA-T4. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRenJi Hospital